Soligenix’s (SNGX) Buy Rating Reaffirmed at Maxim Group

Maxim Group restated their buy rating on shares of Soligenix Inc (OTC:SNGX) in a research note issued to investors on Monday morning. Maxim Group currently has a $4.00 price objective on the stock.

Soligenix (OTC:SNGX) traded down 4.09% during midday trading on Monday, hitting $2.11. 26,422 shares of the company traded hands. The stock has a 50 day moving average price of $2.47 and a 200-day moving average price of $2.56. The company’s market cap is $11.97 million. Soligenix has a 12-month low of $2.10 and a 12-month high of $14.40.

COPYRIGHT VIOLATION WARNING: “Soligenix’s (SNGX) Buy Rating Reaffirmed at Maxim Group” was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.thestockobserver.com/2017/06/20/soligenixs-sngx-buy-rating-reaffirmed-at-maxim-group-2.html.

About Soligenix

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Receive News & Ratings for Soligenix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply